Antiplatelet prasugrel offers coronary stent benefits
Antiplatelet agent prasugrel could offer improved outcomes in patients who have had at least one coronary stent, US researchers report.
A comparison of the combination of thienopyridine, prasugrel and aspirin with clopidogrel plus aspirin in more than 12,800 patients found fewer ischaemic events with the newer combination.
Prasugel reduced definite stent thrombosis by 58% and definite, probable or possible stent thrombosis by 44% compared with the clopidogrel combination.
The Lancet 2008, early online publication